RecruitingGastroesophageal Adenocarcinoma

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

6 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Sponsor: AstraZeneca

You may qualify if…

✓ Histologically documented gastric, GEJ, or esophageal adenocarcinoma with resectable disease
✓ Participants who are CLDN18.2-positive in Sub-study 1 or HER2-positive in Sub-study 2; no specific requirements for Sub-study 3
✓ Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
✓ Adequate organ and bone marrow function
✓ Body weight \> 35 kg

You may not qualify if…

✕ Participants had any prior anti-cancer treatment or surgery for the current gastric, GEJ, or esophageal cancer.
✕ Active or prior documented autoimmune or inflammatory disorders requiring systemic treatment with steroids or other immunosuppressive treatment
✕ Central nervous system (CNS) pathology
✕ Uncontrolled infections
✕ Participants with history of (non-infectious) interstitial lung disease (ILD)/pneumonitis, current ILD/pneumonitis, or suspected ILD/pneumonitis
✕ History of another primary malignancy
✕ Participants with any known or suspicious distant metastasis
✕ Uncontrolled hepatitis B and/or chronic or active hepatitis B

Where it's recruiting

Newark

Washington D.C.

Fairway

North Shores

Pittsburgh

Source: ClinicalTrials.gov · NCT07069712 · last updated 2026-10-16